Cambridge Investment Research Advisors’s Puma Biotechnology PBYI Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,563	Closed	-$80K	–	4146
2026 Q1	$80K	Sell	12,563 -46,754	-79%	-$301K	﹤0.01%	3816
2025 Q4	$353K	Buy	59,317 +8,494	+17%	+$45.1K	﹤0.01%	3035
2025 Q3	$270K	Buy	+50,823	New	+$216K	﹤0.01%	3199
2022 Q4	–	Sell	-14,945	Closed	-$35K	–	3187
2022 Q3	$35K	Buy	+14,945	New	+$43.6K	﹤0.01%	2968
2018 Q1	–	Sell	-12,632	Closed	-$1.25M	–	2213
2017 Q4	$1.25M	Hold	12,632	–	–	0.01%	804
2017 Q3	$1.51M	Buy	+12,632	New	+$1.17M	0.02%	642

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors's PBYI Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of Puma Biotechnology (PBYI) in Q2 2026, closing a stake of 12,563 shares — an estimated $80K sold.

Cambridge Investment Research Advisors first reported a position in PBYI in Q3 2017 and held it in 6 quarters. The position peaked at $1.51M in Q3 2017. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

Cambridge Investment Research Advisors reported no remaining Puma Biotechnology position as of Q2 2026 after selling out during the quarter.
Cambridge Investment Research Advisors sold 12,563 Puma Biotechnology shares in Q2 2026, an estimated $80K.
Cambridge Investment Research Advisors first reported a position in Puma Biotechnology in Q3 2017 and held it in 6 quarters.
Cambridge Investment Research Advisors's Puma Biotechnology position peaked at $1.51M in Q3 2017.
161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.